When starting a biotech company, there are many costs associated with clinical translation. To defray the cost of building a vivarium from scratch to execute animal studies, a contract vivarium provides an attractive alternative. I talked with John Fogarty of Mispro to learn more about what a contract vivarium is and what Mispro offers specifically.

Interested in learning more about a career transition from PhD scientist to patent lawyer? We interviewed two individuals who work at Wilson Sonsini, one of the leading firms for helping biotech companies secure IP through the U.S. patent system.

Logan Leak, SBG Communications Team member, sat down for an interview with Shahram Seyedin-Noor, founder of Civilization Ventures, to learn more about the firm’s philosophy on biotech investing. Click below to read some excerpts from their conversation.

Pillar VC is a venture capital firm focused on supporting founders through seed- and early-stage funding. As an official partner of Stanford Biotechnology Group, Pillar is committed to a close relationship with Stanford students who are interested in learning more about startups and venture capital in the biotechnology space. Communications team member Logan Leak sat down with Tony Kulesa, Principal at Pillar who focuses on biotechnology investments specifically, to learn more about Pillar’s mission and philosophy. Read more at the link below.

The US healthcare system is grappling with a severe shortage of essential medications – a staggering 99% of hospital pharmacists are reporting drug shortages. In this post, Niraj Mehta, PhD student at Stanford, navigates through the crises enveloping the drug manufacturing industry, elucidating how fragile supply chains, paradoxical market incentives, and inadequate regulatory oversight are threatening to wreck US drug supplies. Niraj argues that generic drugs are a vital pillar of the US healthcare industry and advocates for urgent rectifications within market and regulatory landscapes.

SVB’s failure from a bad interest rate bet will be felt across the biotech industry. The Fed stopped a widespread crisis by guaranteeing deposits, but the structural damage has been done.